Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter (O) September 25, 2009

Production of strontium-82 for the Cardiogen® PET generator: a project of the Department of Energy Virtual Isotope Center

  • D. R. Phillips , E. J. Peterson , W.A. Taylor , D. J. Jamriska , V. T. Hamilton , J. J. Kitten , F. O. Valdez , L. L. Salazar , L. R. Pitt , R. C. Heaton , K.L. Kolsky and L.F. Mausner
From the journal Radiochimica Acta

In December of 1989, the United States Food and Drug Administration approved 82Rb chloride in saline solution for cardiological perfusion imaging by positron emission tomography (PET). The solution is derived from a 82Sr generator system that is presently manufactured by Bristol Myers Squibb and distributed for clinical application in the United States by Bracco Diagnostics, Inc. Many years of research and development by people in several institutions led up to the approval for clinical use. Currently, there are about 15 sites in the U.S. that perform clinical myocardial perfusion imaging by PET using 82Rb chloride from the generator. In order to manufacture the generators, Bristol Myers Squibb requires about 1600 mCi of 82Sr every 30 days. The United States Department of Energy and MDS Nordion, Canada are the current suppliers with qualified Drug Master Files for the production and distribution of this nuclide for the Cardiogen® generator. These two entities have worked together over the years to assure the regular, reliable supply of the 82Sr. Here we describe the facilities and methods used by the Department of Energy in its Virtual Isotope Center to make and distribute the nuclide.

Published Online: 2009-9-25
Published in Print: 2000-3-1

© 2015 Oldenbourg Wissenschaftsverlag GmbH, Rosenheimer Str. 145, 81671 München

Downloaded on 23.4.2024 from https://www.degruyter.com/document/doi/10.1524/ract.2000.88.3-4.149/html
Scroll to top button